Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 AUD | -2.60% | +2.74% | +8.70% |
17/04 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
17/04 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+8.70% | 51.87M | |
-6.03% | 3.09B | |
+3.48% | 190M | |
-14.58% | 83.65M | |
-47.23% | 51.92M |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial